Termin vereinbaren

Clinical & Real-world evidence

Learn more about how the FreeStyle Libre portfolio is used in real life by patients and their Health Care Professionals and what results could be achieved.

CATEGORY

All

IMPACT Study

The IMPACT study was the first randomized controlled trial (RCT) to evaluate the efficacy and safety of the FreeStyle Libre system₼ compared to self-monitoring of blood glucose (SMBG) in adults with well-controlled type 1 diabetes.1

icon T1DT1D

LEARN MORE

FLASH-UK Study

The FLASH-UK study demonstrated that intermittently scanned continuous glucose monitoring (isCGM) with the FreeStyle Libre 2 system provided superior clinical benefits compared to SMBG in people with type 1 diabetes (T1D).9

icon T1DT1D

LEARN MORE

SELFY Study

The independent SELFY study showed that the FreeStyle Libre system₼ improved glycemic control in children with diabetes compared to SMBG.2

icon T1D (Pediatrics)T1D (Pediatrics)

LEARN MORE

Yaron et al. Study

This RCT indicated that using FreeStyle Libre systems in patients with type 2 diabetes on multiple daily injections (MDI) may lead to improved treatment satisfaction and a significant reduction in HbA1c without increasing the risk of hypoglycemia.10

icon T2D MDIT2D MDI

LEARN MORE

REPLACE Study

The open-label RCT REPLACE demonstrated that the FreeStyle Libre system₼ can safely and effectively replace SMBG for type 2 diabetes (T2D) patients on intensive insulin therapy.3

icon T2D MDIT2D MDI

LEARN MORE

Wada et al. Study

The RCT by Wada et al. showed that flash glucose monitoring helps achieve better glycemic control than conventional SMBG in non-insulin-treated type 2 diabetes.4

icon T2D beyond MDIT2D beyond MDI

LEARN MORE

FLAMINGO Study

The Flamingo RCT analyzed the effects of the FreeStyle Libre flash glucose monitoring system₼ compared to SMBG on glycemic control and perinatal outcomes in pregnant women with gestational diabetes mellitus (GDM).5

icon Gestational DiabetesGestational Diabetes

LEARN MORE

RELIEF Study (Riveline et al.)

The 24-month follow-up of the RELIEF study6 showed a sustained reduction in hospitalization rates for acute diabetic events in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) in France.11

icon T1D T2D MDIT1D / T2D MDI

LEARN MORE

RELIEF Study (Roussel et al.)

The RELIEF study by Roussel and colleagues, published in Diabetes Care, demonstrated a reduction in ketoacidosis rates in people with type 1 and type 2 diabetes after initiating flash glucose monitoring in France.6

icon T1D T2D MDIT1D / T2D MDI

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

icon T1D T2D MDI (Pediatrics)T1D / T2D MDI (Pediatrics)

LEARN MORE

REFER Study

The REFER study showed glycemic benefits, including improved HbA1c, using FreeStyle Libre systems in type 2 diabetes patients managed with basal and bolus insulin in diabetes centers across Europe.7

icon T2D MDIT2D MDI

LEARN MORE

RELIEF Study (Guerci et al.)

In this subgroup analysis of the RELIEF study, initiating FreeStyle Libre system₼ in patients with type 2 diabetes on basal insulin led to a decrease in hospitalizations for acute diabetes events.13

icon T2D beyond MDIT2D beyond MDI

LEARN MORE

ELLIOT et al. Study

This Canadian real-world retrospective study showed significantly reduced HbA1c following the initiation of flash glucose monitoring technology to support the management of type 2 diabetes treated with basal insulin.8

icon T2D beyond MDIT2D beyond MDI

LEARN MORE

Type 1 Diabetes

IMPACT Study

The IMPACT study was the first randomized controlled trial (RCT) to evaluate the efficacy and safety of the FreeStyle Libre system₼ compared to self-monitoring of blood glucose (SMBG) in adults with well-controlled type 1 diabetes.1

icon T1DT1D

LEARN MORE

FLASH-UK Study

The FLASH-UK study demonstrated that intermittently scanned continuous glucose monitoring (isCGM) with the FreeStyle Libre 2 system provided superior clinical benefits compared to SMBG in people with type 1 diabetes (T1D).9

icon T1DT1D

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

icon T1D T2D MDI (Pediatrics)T1D / T2D MDI (Pediatrics)

LEARN MORE

RELIEF Study (Riveline et al.)

The 24-month follow-up of the RELIEF study6 showed a sustained reduction in hospitalization rates for acute diabetic events in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) in France.11

icon T1D T2D MDIT1D / T2D MDI

LEARN MORE

RELIEF Study (Roussel et al.)

The RELIEF study by Roussel and colleagues, published in Diabetes Care, demonstrated a reduction in ketoacidosis rates in people with type 1 and type 2 diabetes after initiating flash glucose monitoring in France.6

icon T1D T2D MDIT1D / T2D MDI

LEARN MORE

SELFY Study

The independent SELFY study showed that the FreeStyle Libre system₼ improved glycemic control in children with diabetes compared to SMBG.2

icon T1D (Pediatrics)T1D (Pediatrics)

LEARN MORE

Type 2 Diabetes (Multiple Daily Injections)

Yaron et al. Study

This RCT indicated that using FreeStyle Libre systems in patients with type 2 diabetes on multiple daily injections (MDI) may lead to improved treatment satisfaction and a significant reduction in HbA1c without increasing the risk of hypoglycemia.10

icon T2D MDIT2D MDI

LEARN MORE

REPLACE Study

The open-label RCT REPLACE demonstrated that the FreeStyle Libre system₼ can safely and effectively replace SMBG for type 2 diabetes (T2D) patients on intensive insulin therapy.3

icon T2D MDIT2D MDI

LEARN MORE

REFER Study

The REFER study showed glycemic benefits, including improved HbA1c, using FreeStyle Libre systems in type 2 diabetes patients managed with basal and bolus insulin in diabetes centers across Europe.7

icon T2D MDIT2D MDI

LEARN MORE

RELIEF Study (Riveline et al.)

The 24-month follow-up of the RELIEF study6 showed a sustained reduction in hospitalization rates for acute diabetic events in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) in France.11

icon T1D T2D MDIT1D / T2D MDI

LEARN MORE

RELIEF Study (Roussel et al.)

The RELIEF study by Roussel and colleagues, published in Diabetes Care, demonstrated a reduction in ketoacidosis rates in people with type 1 and type 2 diabetes after initiating flash glucose monitoring in France.6

icon T1D T2D MDIT1D / T2D MDI

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

icon T1D T2D MDI (Pediatrics)T1D / T2D MDI (Pediatrics)

LEARN MORE

Type 2 Diabetes (beyond Multiple Daily Injections)

Wada et al. Study

The RCT by Wada et al. showed that flash glucose monitoring helps achieve better glycemic control than conventional SMBG in non-insulin-treated type 2 diabetes.4

icon T2D beyond MDIT2D beyond MDI

LEARN MORE

RELIEF Study (Guerci et al.)

In this subgroup analysis of the RELIEF study, initiating FreeStyle Libre system₼ in patients with type 2 diabetes on basal insulin led to a decrease in hospitalizations for acute diabetes events.13

icon T2D beyond MDIT2D beyond MDI

LEARN MORE

ELLIOT et al. Study

This Canadian real-world retrospective study showed significantly reduced HbA1c following the initiation of flash glucose monitoring technology to support the management of type 2 diabetes treated with basal insulin.8

icon T2D beyond MDIT2D beyond MDI

LEARN MORE

Pediatrics

SELFY Study

The independent SELFY study showed that the FreeStyle Libre system₼ improved glycemic control in children with diabetes compared to SMBG.2

icon T1D (Pediatrics)T1D (Pediatrics)

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

icon T1D T2D MDI (Pediatrics)T1D / T2D MDI (Pediatrics)

LEARN MORE

Gestational Diabetes

FLAMINGO Study

The Flamingo RCT analyzed the effects of the FreeStyle Libre flash glucose monitoring system₼ compared to SMBG on glycemic control and perinatal outcomes in pregnant women with gestational diabetes mellitus (GDM).5

icon Gestational DiabetesGestational Diabetes

LEARN MORE

CATEGORY

All

IMPACT Study

The IMPACT study was the first randomized controlled trial (RCT) to evaluate the efficacy and safety of the FreeStyle Libre system₼ compared to self-monitoring of blood glucose (SMBG) in adults with well-controlled type 1 diabetes.1

T1D

LEARN MORE

FLASH-UK Study

The FLASH-UK study demonstrated that intermittently scanned continuous glucose monitoring (isCGM) with the FreeStyle Libre 2 system provided superior clinical benefits compared to SMBG in people with type 1 diabetes (T1D).9

T1D

LEARN MORE

Wada et al. Study

The RCT by Wada et al. showed that flash glucose monitoring helps achieve better glycemic control than conventional SMBG in non-insulin-treated type 2 diabetes.4

T2D beyond MDI

LEARN MORE

Yaron et al. Study

This RCT indicated that using FreeStyle Libre systems in patients with type 2 diabetes on multiple daily injections (MDI) may lead to improved treatment satisfaction and a significant reduction in HbA1c without increasing the risk of hypoglycemia.10

T2D MDI

LEARN MORE

REPLACE Study

The open-label RCT REPLACE demonstrated that the FreeStyle Libre system₼ can safely and effectively replace SMBG for type 2 diabetes (T2D) patients on intensive insulin therapy.3

T2D MDI

LEARN MORE

FLAMINGO Study

The Flamingo RCT analyzed the effects of the FreeStyle Libre flash glucose monitoring system₼ compared to SMBG on glycemic control and perinatal outcomes in pregnant women with gestational diabetes mellitus (GDM).5

Gestational Diabetes

LEARN MORE

Type 1 Diabetes

IMPACT Study

The IMPACT study was the first randomized controlled trial (RCT) to evaluate the efficacy and safety of the FreeStyle Libre system₼ compared to self-monitoring of blood glucose (SMBG) in adults with well-controlled type 1 diabetes.1

T1D

LEARN MORE

FLASH-UK Study

The FLASH-UK study demonstrated that intermittently scanned continuous glucose monitoring (isCGM) with the FreeStyle Libre 2 system provided superior clinical benefits compared to SMBG in people with type 1 diabetes (T1D).9

T1D

LEARN MORE

Type 2 Diabetes (Multiple Daily Injections)

Yaron et al. Study

This RCT indicated that using FreeStyle Libre systems in patients with type 2 diabetes on multiple daily injections (MDI) may lead to improved treatment satisfaction and a significant reduction in HbA1c without increasing the risk of hypoglycemia.10

T2D MDI

LEARN MORE

REPLACE Study

The open-label RCT REPLACE demonstrated that the FreeStyle Libre system₼ can safely and effectively replace SMBG for type 2 diabetes (T2D) patients on intensive insulin therapy.3

T2D MDI

LEARN MORE

Type 2 Diabetes (beyond Multiple Daily Injections)

Wada et al. Study

The RCT by Wada et al. showed that flash glucose monitoring helps achieve better glycemic control than conventional SMBG in non-insulin-treated type 2 diabetes.4

T2D beyond MDI

LEARN MORE

Pediatrics

Gestational Diabetes

FLAMINGO Study

The Flamingo RCT analyzed the effects of the FreeStyle Libre flash glucose monitoring system₼ compared to SMBG on glycemic control and perinatal outcomes in pregnant women with gestational diabetes mellitus (GDM).5

Gestational Diabetes

LEARN MORE

CATEGORY

All

SELFY Study

The independent SELFY study showed that the FreeStyle Libre system₼ improved glycemic control in children with diabetes compared to SMBG.2

T1D (Pediatrics)

LEARN MORE

RELIEF Study (Riveline et al.)

The 24-month follow-up of the RELIEF study6 showed a sustained reduction in hospitalization rates for acute diabetic events in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) in France.11

T1D / T2D MDI

LEARN MORE

RELIEF Study (Roussel et al.)

The RELIEF study by Roussel and colleagues, published in Diabetes Care, demonstrated a reduction in ketoacidosis rates in people with type 1 and type 2 diabetes after initiating flash glucose monitoring in France.6

T1D / T2D MDI

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

T1D / T2D MDI (Pediatrics)

LEARN MORE

REFER Study

The REFER study showed glycemic benefits, including improved HbA1c, using FreeStyle Libre systems in type 2 diabetes patients managed with basal and bolus insulin in diabetes centers across Europe.7

T2D MDI

LEARN MORE

RELIEF Study (Guerci et al.)

In this subgroup analysis of the RELIEF study, initiating FreeStyle Libre system₼ in patients with type 2 diabetes on basal insulin led to a decrease in hospitalizations for acute diabetes events.13

T2D beyond MDI

LEARN MORE

ELLIOT et al. Study

This Canadian real-world retrospective study showed significantly reduced HbA1c following the initiation of flash glucose monitoring technology to support the management of type 2 diabetes treated with basal insulin.8

T2D beyond MDI

LEARN MORE

Type 1 Diabetes

SELFY Study

The independent SELFY study showed that the FreeStyle Libre system₼ improved glycemic control in children with diabetes compared to SMBG.2

T1D (Pediatrics)

LEARN MORE

RELIEF Study (Riveline et al.)

The 24-month follow-up of the RELIEF study6 showed a sustained reduction in hospitalization rates for acute diabetic events in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) in France.11

T1D / T2D MDI

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

T1D / T2D MDI (Pediatrics)

LEARN MORE

RELIEF Study (Roussel et al.)

The RELIEF study by Roussel and colleagues, published in Diabetes Care, demonstrated a reduction in ketoacidosis rates in people with type 1 and type 2 diabetes after initiating flash glucose monitoring in France.6

T1D / T2D MDI

LEARN MORE

Type 2 Diabetes (Multiple Daily Injections)

RELIEF Study (Roussel et al.)

The RELIEF study by Roussel and colleagues, published in Diabetes Care, demonstrated a reduction in ketoacidosis rates in people with type 1 and type 2 diabetes after initiating flash glucose monitoring in France.6

T1D / T2D MDI

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

T1D / T2D MDI (Pediatrics)

LEARN MORE

REFER Study

The REFER study showed glycemic benefits, including improved HbA1c, using FreeStyle Libre systems in type 2 diabetes patients managed with basal and bolus insulin in diabetes centers across Europe.7

T2D MDI

LEARN MORE

RELIEF Study (Riveline et al.)

The 24-month follow-up of the RELIEF study6 showed a sustained reduction in hospitalization rates for acute diabetic events in people with type 1 diabetes (T1D) or type 2 diabetes (T2D) in France.11

T1D / T2D MDI

LEARN MORE

Type 2 Diabetes (beyond Multiple Daily Injections)

RELIEF Study (Guerci et al.)

In this subgroup analysis of the RELIEF study, initiating FreeStyle Libre system₼ in patients with type 2 diabetes on basal insulin led to a decrease in hospitalizations for acute diabetes events.13

T2D beyond MDI

LEARN MORE

ELLIOT et al. Study

This Canadian real-world retrospective study showed significantly reduced HbA1c following the initiation of flash glucose monitoring technology to support the management of type 2 diabetes treated with basal insulin.8

T2D beyond MDI

LEARN MORE

Pediatrics

SELFY Study

The independent SELFY study showed that the FreeStyle Libre system₼ improved glycemic control in children with diabetes compared to SMBG.2

T1D (Pediatrics)

LEARN MORE

EVANS et al. Study

This meta-analysis of 75 real-world observational studies observed a significant and sustained reduction in HbA1c with the FreeStyle Libre system₼ in patients with T1D and T2D.12

T1D / T2D MDI (Pediatrics)

LEARN MORE

Gestational Diabetes

Disclaimer & References

 ₼ Sale of the original FreeStyle Libre system has been discontinued in EU & UK markets. In these markets, the FreeStyle Libre 2 and 3 systems are for sale, providing the same benefits as the original FreeStyle Libre system, with the added functionalities of optional Real-Time Alarms

  1. Bolinder J., Lancet. (2016): https://doi.org/10.1016/S0140-6736(16)31535-5.
  2. Campbell, FM. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735.
  3. Haak, T. Diabetes Therapy (2017): https://doi.org/10.1007/s13300-016-0223-6.
  4. Wada, E. BMJ Open Diabetes Res Care (2020): https://doi.org/10.1136/bmjdrc-2019-001115.
  5. Majewska, A. Acta Diabetol (2023): https://doi.org/10.1007/s00592-023-02091-2. Epub 2023 May 10.
  6. Roussel R., Diabetes Care. (2021): https://doi.org/10.2337/dc20-1690.
  7. Kroger J., Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9.
  8. Elliott, T. Diab Vasc Dis Res (2021): https://doi.org/10.1177/14791641211021374.
  9. Leelarathna, L. N Engl J Med. (2022): DOI: 10.1056/NEJMoa2205650.
  10. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166.
  11. Riveline, JP. Diabetes Technol Ther (2022): https://doi.org/10.1089/dia.2022.0085.
  12. Evans M., Diabetes Ther. (2022): http://doi.org/10.1007/s13300-022-01253-9.
  13. Guerci, B. DiabetesTechnol & Ther. (2023): https://doi.org/10.1089/dia.2022.0271

 

 
1. Die FreeStyle LibreLink App und die FreeStyle Libre 3 App sind nur mit bestimmten Mobilgeräten und Betriebssystemen kompatibel. Bevor Sie die App nutzen möchten, besuchen Sie bitte die Webseite www.freestyle.abbott um mehr Informationen zur Gerätekompatibilität zu erhalten.
 
2. Das Setzen eines Sensors erfordert ein Einführen des Sensorfilaments unter die Haut. Der Sensor kann bis zu 15 Tage lang getragen werden
 
3. Eine zusätzliche Prüfung der Glukosewerte mittels eines Blutzucker-Messgeräts ist erforderlich, wenn die Symptome nicht mit den Messwerten oder den Alarmen des Systems übereinstimmen.
 
4. Die Aussage basiert auf der Anzahl der Nutzer:innen des FreeStyle Libre Messsystems weltweit im Vergleich zu der Nutzeranzahl anderer führender sensorbasierter Glukose-Messsysteme für den persönlichen Gebrauch. Daten liegen vor. Abbott Diabetes Care Inc.
 
5. Der Sensor ist 60 Minuten nach der Aktivierung für die Glukosemessung bereit.
 
6. Der Sensor ist in bis zu 1 m Wassertiefe für die Dauer von bis zu 30 Minuten wasserfest.
 
7. Im Vergleich mit anderen von Patient:innen selbst anzubringenden Sensoren. Daten liegen vor. Abbott Diabetes Care.
 
8. Daten liegen vor. Abbott Diabetes Care.
 
9. LibreView ist eine cloudbasierte Anwendung. Die LibreView Daten werden in ein virtuelles nicht öffentliches Netzwerk übertragen und auf einer SQL-Server-Datenbank gehostet. Die Daten sind auf Dateiebene verschlüsselt. Die Verschlüsselung und Art der Schlüsselspeicherfunktionen verhindern, dass der Cloud-Hosting-Anbieter (Amazon Web Services) die Daten einsehen kann. Bei Nutzung von LibreView in Österreich werden die Daten auf Servern in der EU gehostet. Der Zugang zum jeweiligen Nutzer Account ist passwortgeschützt.
 
10. Im Vergleich mit anderen am Körper zu tragenden Sensoren. Daten liegen vor. Abbott Diabetes Care.
 
11. Für ein vollständiges glykämisches Profil muss der FreeStyle Libre 2 Plus oder der FreeStyle Libre 3 Plus Sensor nach dem Auftreten eines Signalverlustes gescannt und alle 15 Tage ersetzt werden.
 
12. Die Nutzung von LibreLinkUp erfordert eine Registrierung bei LibreView.
 
13. Glukosealarme von verbundenen Nutzer:innen werden an die LibreLinkUp App übertragen, wenn der Sensor mit dem Smartphone gestartet wurde und die Alarme in den Freestyle Libre System Apps aktiviert sind.
 
14. Es besteht die Möglichkeit, die LibreLinkUp Einladung anzunehmen und damit Benachrichtigungen und Warnhinweise zu erhalten oder diese abzulehnen. Eine Entscheidung hierüber sollte basierend auf Kenntnissen und Erfahrungen getroffen werden, bei dem Erhalt eines zu hohen oder zu niedrigen Glukosewerts angemessen reagieren zu können.
 
15. Alarme sind standardgemäß ausgeschaltet und müssen eingeschaltet werden.
 
16. Das Teilen der Daten aus der FreeStyle LibreLink App oder der FreeStyle Libre 3 App erfordert eine Registrierung bei LibreView.
 
17. Die Übertragung der Daten zwischen den Apps erfordert eine Internetverbindung.
 
18. Für ein vollständiges glykämisches Profil muss der FreeStyle Libre 3 Plus Sensor alle 15 Tage ersetzt werden
 
19. Der Alarm bei Signalverlust wird automatisch aktiviert, sobald ein Glukose-Alarm zum ersten Mal eingeschaltet wird. Der Alarm bei Signalverlust kann jederzeit aus- und wieder eingeschaltet werden.
 
20. Eine kompatible mylife YpsoPump wird benötigt, um die mylife CamAPS FX App für die automatisierte Insulinabgabe nutzen zu können
 
21. Die CamAPS FX App ist nur mit bestimmten Mobilgeräten und Betriebssystemen kompatibel. Bevor Sie die App nutzen möchten, besuchen Sie bitte die Webseite www.camdiab.com/de, um mehr Informationen zur Gerätekompatibilität zu erhalten.
 
22. Die FreeStyle LibreLink App funktioniert mit FreeStyle Libre 2 Plus Sensoren und ist nur mit NovoPen® 6 und NovoPen Echo® Plus kompatibel.
 
23. Die FreeStyle Libre Messsysteme sind zertifiziert für Kinder ab 2 Jahren, sowie Erwachsene, einschließlich Schwangeren. Die Aufsichtspflicht über die Anwendung und die Auswertung von FreeStyle Libre Messsystemen bei Kindern bis zur Vollendung des 12. Lebensjahres obliegt der Verantwortung einer volljährigen Person.
 
24. No YSI measurements were obtained for ages 2-5 years (Für Kinder im Alter von 2 bis 5 Jahren wurden keine YSI-Messungen durchgeführt.)
 
A. Alva S et al. Journal of Diabetes Science and Technology, 2020 | DOI: 10.1177/1932296820958754
 
B. Battelino Tadej, et al., Diabetes Care. 2019;42(8):1593-1603.
 
C. Alva S et al. Diabetes Ther. 2023 Mar 6. doi: 10.1007/s13300-023-01385-6. Online ahead of print.
 
D. Bolinder, Jan et al. The Lancet. 2016; 388 (10057): 2254-2263.
 
E. Charleer Sara et al., Diabetes Care. 2020;43(2):389-397.
 
F. Dunn T et al. Diabetes Res Clin Pract. 2018 Mar;137:37-46.
 
G. Evans M et al. Diabetes Ther. 2022. https://doi.org/10.1007/s13300-022-01253-9
 
H. Fokkert M et al., BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.
 
I. Haak T et al. Diabetes Therapy. 2017; 8 (1): 55–73.
 
J. Lang J et al., [Poster 972]. Diabetes 2019;68(suppl 1). https://doi.org/10.2337/db19-972-P.
 
K. Yaron M et al. Diabetes Care 2019; 42 (7): 1178-1184.
 
L. Bailey T et al. Diabetes Technology Ther. 2015;17(11):787-794.
 
M. Leelarathna L, N Engl J Med. 2022 Oct 20;387(16):1477-1487.
 
N. Gibb Fraser W et al. British Journal of Diabetes. 2020 Jun 5;20(1):32-40.
 
O. Kröger J, et al. Diabetes Ther, 2020; 11(1):279-291
 
P. UK Hypoglycaemia Study Group: Diabetologia 2007, 50:1140–1147.
 
Q. Ajjan RA & Owen KR Curr Diab Rep 2014; 14: 559-566.
 
R. Kilpatrick ES et al Diabetologia 2008; 51: 365-371.
 
S. Lu J, et al. Diabetes Technol Ther. 22. Feb. 2020:72–78.
 
T. Beck RW et al. Diabetes Care 2019;42:400–405.
 
U. Lu J et al. Diabetes Care 2018;41:2370-3276.
 
V. Li F et al. Diabetes Res Clin Pract. Aug. 2020;166:108289. doi: 10.1016/j.diabres.2020.108289.
 
W. Pickup JC et al. Diabetes Care 2015;38(4):544-550.
 
X. American Diabetes Association Professional Practice Committee. Diabetes Care 2022;45 (Suppl. 1):S60–S82.
 
Y. Campbell FM et al. Pediatr Diabetes 2018;19(7):1294–301.
 
Z. Deshmukh H, et al. Assoc of Brit Clin Diabetol (ABCD) Nationwide Audit. Diabetes Care 2020;43:2153–2160.
 
AA. Kao et al. Journal of Diabetes Science and Technology. 2022 Jan;16(1):259-60.
 
* Mo-Fr (werktags) von 08:00-18:00 Uhr, Sa (werktags) von 09:00 – 17:00 Uhr. Kostenlos aus dem österreichischen Festnetz und Mobilfunknetz.
 
Abbildungen sind Agenturfotos, mit Models gestellt. Glukosedaten dienen zur Illustration, keine echten Patientendaten.
 
Das Sensorgehäuse, FreeStyle, Libre, und damit verbundene Markennamen sind Marken von Abbott. Sonstige Marken sind Eigentum der jeweiligen Hersteller.
 
Apple und das Apple Logo sind eingetragenen Marken von Apple Inc., in den USA und anderen Ländern. App Store ist ein Warenzeichen von Apple Inc.
 
Google Play und das Google Play-Logo sind Marken von Google LLC.
 
NovoPen® 6 und NovoPen Echo® Plus sind eingetragene Marken der Novo Nordisk A/S.
 
mylife Loop und YpsoPump sind eingetragene Handelsmarken von Ypsomed AG. CamAPS ist eine eingetragene Marke von CamDiab Ltd. Andere Handelsmarken und Handelsnamen sind Eigentum der jeweiligen Inhaber. Für die Nutzung des FreeStyle Libre 3 Plus Sensors mit mylife Loop konsultieren Sie bitte das Benutzerhandbuch der mylife CamAPSFX App.
 
 
WARUM FREESTYLE LIBRE?
FreeStyle Portfolio
Wissensdatenbank
Hilfe & Kontakt
Abbott Logo

Copyright © 2025 Abbott. Das Sensorgehäuse, FreeStyle, Libre und damit verbundene Markennamen sind Marken von Abbott. Sonstige Markennamen und Logos sind Eigentum der jeweiligen Hersteller.

Firmenanschrift: Abbott GmbH, Perfektastr. 84 A, 1230 Wien, Tel. +43 1 891 22 0 (kostenlos)

Möchten Sie diese Seite verlassen?

Der untenstehende Button «Ja» leitet Sie auf andere Websites als die von Abbott Laboratories weiter. Links, die zu anderen Websites führen, stehen nicht unter der Kontrolle von Abbott Laboratories, und Abbott Laboratories ist nicht verantwortlich für den Inhalt einer solchen Website oder eines auf einer solchen Website enthaltenen Links. Abbott Laboratories stellt Ihnen diese Links nur als Service zur Verfügung, und die Aufnahme eines Links bedeutet nicht, dass Abbott Laboratories die betreffende Website befürwortet.

Diese Website ist nur für medizinische Fachkräfte, die ihre Tätigkeit in Österreich ausüben.

www.pro.freestyle.abbott/at-de/ ist eine Website mit Produktinformationen und nur für in Österreich ansässige und praktizierende Angehörige der Gesundheitsberufe bestimmt.

Wenn Sie in einem anderen Land ansässig sind, wenden Sie sich bitte an Ihren örtlichen Abbott-Vertreter, um die korrekten Informationen über die in Ihrem Land erhältlichen Produkte zu erhalten.